Lilly, Novo lock horns in India's obesity drug race
23.12.2025
HYDERABAD, India, Dec 24 () - Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year. Novo's strategy emphasizes price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early.